(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 36.54% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Syndax Pharmaceuticals's revenue in 2026 is $252,251,000.On average, 14 Wall Street analysts forecast SNDX's revenue for 2026 to be $28,793,845,381, with the lowest SNDX revenue forecast at $26,568,561,998, and the highest SNDX revenue forecast at $31,691,535,821. On average, 14 Wall Street analysts forecast SNDX's revenue for 2027 to be $40,497,121,472, with the lowest SNDX revenue forecast at $34,082,018,814, and the highest SNDX revenue forecast at $48,103,447,257.
In 2028, SNDX is forecast to generate $57,343,909,717 in revenue, with the lowest revenue forecast at $43,755,572,140 and the highest revenue forecast at $76,415,981,345.